Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bullish
Takeda Pharmaceutical
Watchlist
Takeda 4QFY22: Top Line Expands and Pipeline Development Progresses Despite OP Drop
Equity Bottom-Up
363 Views
12 May 2022 11:08
The decline in OP was due to divestitures which remained a key headwind for margins during the last fiscal year. Excluding these, core OP for 4Q was JPY197.3bn (Core OPM of 23.0%).
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Equity Bottom-Up
South Korea
Sell / Short Ideas
Asia ECM
Event-Driven
Japan
Asia Event-Driven
Singapore REITs
India
Philippines
Trending Insights
More »
Nuvama Wealth: The "Blessing in Disguise" Amidst Market Jitters in Jane Street Case
NTT DC REIT IPO: Valuation Insights
Korea Small Cap Gem #38: Infinitt Healthcare
Last Week In Event SPACE: Shibaura, HKBN, NWD, Yichang HEC
China Healthcare Weekly (Jul.6)- Anjoy’s IPO Debut, HEC CJ Pharma's Merger with Sunshine Lake Pharma
Top Unpaywalled Insights
More »
[IO Technicals 2025/27] Bullish Momentum Gains Traction
Oversupply Meets Tepid Demand Weighing Down on Soybean Meal
[IO Technicals 2025/26] Bearish Momentum Intensifies
"The Data Bottleneck in Quant Finance — and How to Break It" With David Forino, CTO of Quanted
The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Takeda: A Deep Dive into Takeda’s Dengue Vaccine
08 Nov 2022
Takeda: Thrilling Journey Ahead with a Dengue Vaccine Launch and New Approvals
31 Oct 2022
Takeda 1Q: Top Line Beat Consensus – Development Pipeline Continues to Progress
29 Jul 2022
Takeda 4QFY22: Top Line Expands and Pipeline Development Progresses Despite OP Drop
12 May 2022
Takeda Strengthens Rare Disease Portfolio Through Tie-Ups with Gene Therapy Developers
06 Apr 2022
Takeda: Key Drugs Continue Growth and Upgrade to Guidance; Pipeline Progress Despite Recent Setbacks
03 Feb 2022
Takeda: Excessive Reaction to Recent Setback in Trials; Drop in Share Price Offer Attractive Entry
10 Jan 2022
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.7
x